Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Marco Cerrano, Paola Berchialla, Matteo Dragani, Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Bruno Martino, Carlo Gambacorti-Passerini, Elisabetta Abruzzese, Chiara Elena, Patrizia Pregno, Antonella Gozzini, Isabella Capodanno, Micaela Bergamaschi, Monica Crugnola, Monica Bocchia, Sara GalimbertiDavide Rapezzi, Alessandra Iurlo, Daniele Cattaneo, Roberto Latagliata, Massimo Breccia, Michele Cedrone, Marco Santoro, Mario Annunziata, Luciano Levato, Fabio Stagno, Francesco Cavazzini, Nicola Sgherza, Valentina Giai, Luigia Luciano, Sabina Russo, Pellegrino Musto, Giovanni Caocci, Federica Sorà, Francesco Iuliano, Francesca Lunghi, Giorgina Specchia, Fabrizio Pane, Dario Ferrero, Michele Baccarani, Giuseppe Saglio

Research output: Contribution to journalArticle

Abstract

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P<0.001). Eighty-eight percent of patients discontinued as per clinical practice, and reasons for stopping treatment were: toxicity (20%), pregnancy (6%), and shared decision between treating physician and patient (62%). After a median follow up of 34 months (range, 12-161) overall estimated TFR was 62% (95%CI: 56;68). At 12 months, TFR was 68% (95%CI: 62;74) for imatinib, 73% (95%CI: 64;83) for second generation TKI. Overall median time to restart treatment was six months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and second generation TKI is feasible and safe in clinical practice.

Original languageEnglish
Pages (from-to)1589-1596
Number of pages8
JournalHaematologica
Volume104
Issue number8
DOIs
Publication statusPublished - Jul 31 2019

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Observational Studies
Therapeutics
Leukemia, Myeloid, Chronic Phase
Retrospective Studies
Physicians
Pregnancy
Imatinib Mesylate

ASJC Scopus subject areas

  • Hematology

Cite this

Fava, C., Rege-Cambrin, G., Dogliotti, I., Cerrano, M., Berchialla, P., Dragani, M., ... Saglio, G. (2019). Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica, 104(8), 1589-1596. https://doi.org/10.3324/haematol.2018.205054

Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice. / Fava, Carmen; Rege-Cambrin, Giovanna; Dogliotti, Irene; Cerrano, Marco; Berchialla, Paola; Dragani, Matteo; Rosti, Gianantonio; Castagnetti, Fausto; Gugliotta, Gabriele; Martino, Bruno; Gambacorti-Passerini, Carlo; Abruzzese, Elisabetta; Elena, Chiara; Pregno, Patrizia; Gozzini, Antonella; Capodanno, Isabella; Bergamaschi, Micaela; Crugnola, Monica; Bocchia, Monica; Galimberti, Sara; Rapezzi, Davide; Iurlo, Alessandra; Cattaneo, Daniele; Latagliata, Roberto; Breccia, Massimo; Cedrone, Michele; Santoro, Marco; Annunziata, Mario; Levato, Luciano; Stagno, Fabio; Cavazzini, Francesco; Sgherza, Nicola; Giai, Valentina; Luciano, Luigia; Russo, Sabina; Musto, Pellegrino; Caocci, Giovanni; Sorà, Federica; Iuliano, Francesco; Lunghi, Francesca; Specchia, Giorgina; Pane, Fabrizio; Ferrero, Dario; Baccarani, Michele; Saglio, Giuseppe.

In: Haematologica, Vol. 104, No. 8, 31.07.2019, p. 1589-1596.

Research output: Contribution to journalArticle

Fava, C, Rege-Cambrin, G, Dogliotti, I, Cerrano, M, Berchialla, P, Dragani, M, Rosti, G, Castagnetti, F, Gugliotta, G, Martino, B, Gambacorti-Passerini, C, Abruzzese, E, Elena, C, Pregno, P, Gozzini, A, Capodanno, I, Bergamaschi, M, Crugnola, M, Bocchia, M, Galimberti, S, Rapezzi, D, Iurlo, A, Cattaneo, D, Latagliata, R, Breccia, M, Cedrone, M, Santoro, M, Annunziata, M, Levato, L, Stagno, F, Cavazzini, F, Sgherza, N, Giai, V, Luciano, L, Russo, S, Musto, P, Caocci, G, Sorà, F, Iuliano, F, Lunghi, F, Specchia, G, Pane, F, Ferrero, D, Baccarani, M & Saglio, G 2019, 'Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice', Haematologica, vol. 104, no. 8, pp. 1589-1596. https://doi.org/10.3324/haematol.2018.205054
Fava, Carmen ; Rege-Cambrin, Giovanna ; Dogliotti, Irene ; Cerrano, Marco ; Berchialla, Paola ; Dragani, Matteo ; Rosti, Gianantonio ; Castagnetti, Fausto ; Gugliotta, Gabriele ; Martino, Bruno ; Gambacorti-Passerini, Carlo ; Abruzzese, Elisabetta ; Elena, Chiara ; Pregno, Patrizia ; Gozzini, Antonella ; Capodanno, Isabella ; Bergamaschi, Micaela ; Crugnola, Monica ; Bocchia, Monica ; Galimberti, Sara ; Rapezzi, Davide ; Iurlo, Alessandra ; Cattaneo, Daniele ; Latagliata, Roberto ; Breccia, Massimo ; Cedrone, Michele ; Santoro, Marco ; Annunziata, Mario ; Levato, Luciano ; Stagno, Fabio ; Cavazzini, Francesco ; Sgherza, Nicola ; Giai, Valentina ; Luciano, Luigia ; Russo, Sabina ; Musto, Pellegrino ; Caocci, Giovanni ; Sorà, Federica ; Iuliano, Francesco ; Lunghi, Francesca ; Specchia, Giorgina ; Pane, Fabrizio ; Ferrero, Dario ; Baccarani, Michele ; Saglio, Giuseppe. / Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice. In: Haematologica. 2019 ; Vol. 104, No. 8. pp. 1589-1596.
@article{dbeba525f4bb45fd86116c0986d3b670,
title = "Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice",
abstract = "It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28{\%} with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P<0.001). Eighty-eight percent of patients discontinued as per clinical practice, and reasons for stopping treatment were: toxicity (20{\%}), pregnancy (6{\%}), and shared decision between treating physician and patient (62{\%}). After a median follow up of 34 months (range, 12-161) overall estimated TFR was 62{\%} (95{\%}CI: 56;68). At 12 months, TFR was 68{\%} (95{\%}CI: 62;74) for imatinib, 73{\%} (95{\%}CI: 64;83) for second generation TKI. Overall median time to restart treatment was six months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and second generation TKI is feasible and safe in clinical practice.",
author = "Carmen Fava and Giovanna Rege-Cambrin and Irene Dogliotti and Marco Cerrano and Paola Berchialla and Matteo Dragani and Gianantonio Rosti and Fausto Castagnetti and Gabriele Gugliotta and Bruno Martino and Carlo Gambacorti-Passerini and Elisabetta Abruzzese and Chiara Elena and Patrizia Pregno and Antonella Gozzini and Isabella Capodanno and Micaela Bergamaschi and Monica Crugnola and Monica Bocchia and Sara Galimberti and Davide Rapezzi and Alessandra Iurlo and Daniele Cattaneo and Roberto Latagliata and Massimo Breccia and Michele Cedrone and Marco Santoro and Mario Annunziata and Luciano Levato and Fabio Stagno and Francesco Cavazzini and Nicola Sgherza and Valentina Giai and Luigia Luciano and Sabina Russo and Pellegrino Musto and Giovanni Caocci and Federica Sor{\`a} and Francesco Iuliano and Francesca Lunghi and Giorgina Specchia and Fabrizio Pane and Dario Ferrero and Michele Baccarani and Giuseppe Saglio",
year = "2019",
month = "7",
day = "31",
doi = "10.3324/haematol.2018.205054",
language = "English",
volume = "104",
pages = "1589--1596",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice

AU - Fava, Carmen

AU - Rege-Cambrin, Giovanna

AU - Dogliotti, Irene

AU - Cerrano, Marco

AU - Berchialla, Paola

AU - Dragani, Matteo

AU - Rosti, Gianantonio

AU - Castagnetti, Fausto

AU - Gugliotta, Gabriele

AU - Martino, Bruno

AU - Gambacorti-Passerini, Carlo

AU - Abruzzese, Elisabetta

AU - Elena, Chiara

AU - Pregno, Patrizia

AU - Gozzini, Antonella

AU - Capodanno, Isabella

AU - Bergamaschi, Micaela

AU - Crugnola, Monica

AU - Bocchia, Monica

AU - Galimberti, Sara

AU - Rapezzi, Davide

AU - Iurlo, Alessandra

AU - Cattaneo, Daniele

AU - Latagliata, Roberto

AU - Breccia, Massimo

AU - Cedrone, Michele

AU - Santoro, Marco

AU - Annunziata, Mario

AU - Levato, Luciano

AU - Stagno, Fabio

AU - Cavazzini, Francesco

AU - Sgherza, Nicola

AU - Giai, Valentina

AU - Luciano, Luigia

AU - Russo, Sabina

AU - Musto, Pellegrino

AU - Caocci, Giovanni

AU - Sorà, Federica

AU - Iuliano, Francesco

AU - Lunghi, Francesca

AU - Specchia, Giorgina

AU - Pane, Fabrizio

AU - Ferrero, Dario

AU - Baccarani, Michele

AU - Saglio, Giuseppe

PY - 2019/7/31

Y1 - 2019/7/31

N2 - It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P<0.001). Eighty-eight percent of patients discontinued as per clinical practice, and reasons for stopping treatment were: toxicity (20%), pregnancy (6%), and shared decision between treating physician and patient (62%). After a median follow up of 34 months (range, 12-161) overall estimated TFR was 62% (95%CI: 56;68). At 12 months, TFR was 68% (95%CI: 62;74) for imatinib, 73% (95%CI: 64;83) for second generation TKI. Overall median time to restart treatment was six months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and second generation TKI is feasible and safe in clinical practice.

AB - It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TKI than with imatinib (P<0.001). Eighty-eight percent of patients discontinued as per clinical practice, and reasons for stopping treatment were: toxicity (20%), pregnancy (6%), and shared decision between treating physician and patient (62%). After a median follow up of 34 months (range, 12-161) overall estimated TFR was 62% (95%CI: 56;68). At 12 months, TFR was 68% (95%CI: 62;74) for imatinib, 73% (95%CI: 64;83) for second generation TKI. Overall median time to restart treatment was six months (IQR 4;11). No progressions occurred. Although our study has the limitation of a retrospective study, our experience within the Italian population confirms that discontinuation of imatinib and second generation TKI is feasible and safe in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85067015537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067015537&partnerID=8YFLogxK

U2 - 10.3324/haematol.2018.205054

DO - 10.3324/haematol.2018.205054

M3 - Article

AN - SCOPUS:85067015537

VL - 104

SP - 1589

EP - 1596

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -